663 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Bought by Raymond James Trust N.A.

Raymond James Trust N.A. purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 663 shares of the company’s stock, valued at approximately $203,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. BlackRock Inc. lifted its position in Medpace by 0.9% during the first quarter. BlackRock Inc. now owns 3,792,694 shares of the company’s stock valued at $620,448,000 after buying an additional 35,121 shares during the period. Wasatch Advisors Inc. lifted its position in Medpace by 12.1% during the first quarter. Wasatch Advisors Inc. now owns 2,728,392 shares of the company’s stock valued at $446,338,000 after buying an additional 294,103 shares during the period. State Street Corp lifted its position in Medpace by 2.5% during the first quarter. State Street Corp now owns 899,855 shares of the company’s stock valued at $147,207,000 after buying an additional 21,868 shares during the period. Dimensional Fund Advisors LP lifted its position in Medpace by 1.5% during the first quarter. Dimensional Fund Advisors LP now owns 656,864 shares of the company’s stock valued at $107,456,000 after buying an additional 9,881 shares during the period. Finally, Invesco Ltd. lifted its position in Medpace by 67.6% during the third quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock valued at $148,159,000 after buying an additional 246,775 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Up 0.1 %

Medpace stock opened at $403.27 on Thursday. The business has a 50-day simple moving average of $364.20 and a two-hundred day simple moving average of $304.29. The company has a market cap of $12.40 billion, a P/E ratio of 45.41, a P/E/G ratio of 2.13 and a beta of 1.38. Medpace Holdings, Inc. has a 52-week low of $179.49 and a 52-week high of $419.42.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 12th. The company reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.22 by $0.24. The business had revenue of $498.40 million during the quarter, compared to the consensus estimate of $498.72 million. Medpace had a return on equity of 63.98% and a net margin of 15.00%. The business’s quarterly revenue was up 26.5% compared to the same quarter last year. During the same period in the previous year, the company posted $2.12 EPS. Research analysts anticipate that Medpace Holdings, Inc. will post 10.53 EPS for the current fiscal year.

Insider Activity at Medpace

In related news, CEO August J. Troendle sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the transaction, the chief executive officer now directly owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CEO August J. Troendle sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the transaction, the chief executive officer now directly owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Susan E. Burwig sold 102 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the completion of the transaction, the vice president now directly owns 15,181 shares in the company, valued at $6,117,943. The disclosure for this sale can be found here. In the last ninety days, insiders sold 189,340 shares of company stock worth $76,651,647. 25.70% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have recently issued reports on MEDP. UBS Group raised Medpace from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $282.00 to $452.00 in a research report on Thursday, February 15th. Deutsche Bank Aktiengesellschaft began coverage on Medpace in a research report on Monday, March 18th. They issued a “hold” rating and a $395.00 price target for the company. StockNews.com lowered Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, March 23rd. Finally, Robert W. Baird lifted their price objective on Medpace from $312.00 to $408.00 and gave the stock an “outperform” rating in a report on Wednesday, February 14th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Medpace presently has a consensus rating of “Moderate Buy” and an average target price of $382.00.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.